专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2012099962A2 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MAKING AND USING THEM 审中-公开
标题翻译：药物组合物及其制备和使用方法
公开(公告)号：WO2012099962A2
公开(公告)日：2012-07-26
申请号：PCT/US2012021724
申请日：2012-01-18
申请人： VICUS THERAPEUTICS LLC , MAKI JOHN , BASCOMB NEWELL , TURNER TIMOTHY J
发明人： MAKI JOHN , BASCOMB NEWELL , TURNER TIMOTHY J
IPC分类号： A61K31/455 , A61K9/06 , A61K9/12 , A61K9/70 , A61K31/133 , A61K31/20
CPC分类号： A61K31/7068 , A61K9/0014 , A61K9/06 , A61K31/133 , A61K31/20 , A61K31/337 , A61K31/404 , A61K31/44 , A61K31/4439 , A61K31/455 , A61K31/4985 , A61K31/506 , A61K31/517
摘要： In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising combinations of beneficial ingredients that in alternative embodiments are serviceable as therapies or palliatives for treating, preventing or improving conditions, states and disease symptoms involving the use of targeted protein kinase inhibitors such as Multi-Kinase Inhibitors (MKIs) or Epidermal Growth Factor Receptor (EGFR) Inhibitors (EGFRIs), or the use of other oral oncolytics, such as capcitabine or erlotinib, known to be associated with drug-induced dermatological toxicity, e.g., in the amelioration or treatment of a cancer, a dermatitis, a rosacea, an eczema, an ichthyosis, or a related condition; and methods for making and using these compositions; and methods for making and using these compositions.
摘要翻译：在替代实施方式中，本发明提供了组合物，例如药物组合物和制剂，制剂，试剂盒和其他制造产品，例如包装在一起或分开包装在泡罩包装，有盖泡罩或泡罩卡中或包装在纸，塑料或玻璃纸包装物（例如收缩包装物），其包含有利成分的组合，其在可选的实施方案中可用作治疗或预防或改善涉及使用靶向蛋白激酶抑制剂的病症，状态和疾病症状的疗法或缓和剂，例如多激酶抑制剂（MKIs）或表皮生长因子受体（EGFR）抑制剂（EGFRIs），或已知与药物诱导的皮肤病学毒性有关的其他口服溶瘤剂如capcitabine或厄洛替尼的用途，例如改善或治疗癌症，皮炎，红斑痤疮，湿疹，鱼鳞病或相关病症; 以及制造和使用这些组合物的方法; 以及制备和使用这些组合物的方法。

12. 发明申请

WO2009023555A1 CAN END WITH COUNTERSINK 审中-公开
标题翻译：可以结束与COUNTERSINK
公开(公告)号：WO2009023555A1
公开(公告)日：2009-02-19
申请号：PCT/US2008/072594
申请日：2008-08-08
申请人： REXAM BEVERAGE CAN COMPANY , FORREST, Randall G. , TURNER, Timothy L.
发明人： FORREST, Randall G. , TURNER, Timothy L.
IPC分类号： B65D17/00 , B65D6/30
CPC分类号： B65D17/08 , B65D17/4012 , Y10S220/906
摘要： A can end (10) for a two-piece beverage can is described. The can end (10) has a center panel (18) positioned about a vertical center axis (50). The center panel (18) has a means for opening the can end (10) located on a public side. A reinforcing bead (16) surrounds the center panel (18). The reinforcing bead (16) has an inner curved portion having a radius of curvature located radially inwardly from an outer curved portion having a radius of curvature. The radius of curvature of the outer curved portion is greater than the radius of curvature of the inner curved portion.
摘要翻译：描述了用于两件式饮料罐的罐端（10）。罐端部（10）具有围绕垂直中心轴线（50）定位的中心面板（18）。中心面板（18）具有用于打开位于公共侧的罐头（10）的装置。一个围绕中心面板（18）的增强珠（16）。加强筋（16）具有内弯曲部分，其具有从具有曲率半径的外弯曲部分径向向内设置的曲率半径。外弯曲部分的曲率半径大于内弯曲部分的曲率半径。

13. 发明申请

WO2008154275A3 PROCESS FOR COMBUSTION OF HIGH VISCOSITY LOW HEATING VALUE LIQUID FUELS 审中-公开
标题翻译：高粘度低温液体燃料燃烧过程
公开(公告)号：WO2008154275A3
公开(公告)日：2009-02-05
申请号：PCT/US2008065879
申请日：2008-06-05
申请人： UNIV NORTH CAROLINA STATE , ROBERTS WILLIAM L , METZGER BRIAN , TURNER TIMOTHY L
发明人： ROBERTS WILLIAM L , METZGER BRIAN , TURNER TIMOTHY L
IPC分类号： F23D11/24 , F23D11/40 , F23D11/44
CPC分类号： F23D11/24 , F23C2900/99009 , F23D11/404 , F23D11/446 , F23D11/448 , F23D2900/11403 , F23D2900/14124 , Y02E20/12 , Y02P30/20
摘要： The present invention is directed to a process for the clean and convenient combustion of high viscosity liquid fuels, such as glycerol, as well as an apparatus useful for carrying such processes. In certain embodiments, the invention provides a process for glycerol combustion comprising providing a combustion apparatus (10) with a glycerol combustion chamber (185) that facilitates reflective heating, pre-heating the glycerol combustion chamber, atomizing the reduced viscosity glycerol, and combining the atomized glycerol with air in the glycerol combustion chamber to thereby completely combust the glycerol. In one embodiment, such as when using a pressure-atomizing nozzle (200), the inventive method may further comprise treating the glycerol to reduce the glycerol viscosity.
摘要翻译：本发明涉及用于清洁和方便地燃烧高粘度液体燃料如甘油的方法，以及用于承载这些方法的装置。在某些实施方案中，本发明提供了一种用于甘油燃烧的方法，包括提供具有甘油燃烧室（185）的燃烧装置（10），所述甘油燃烧室促进反射加热，预热甘油燃烧室，雾化还原性甘油，在甘油燃烧室中用空气雾化甘油，从而完全燃烧甘油。在一个实施例中，例如当使用压力雾化喷嘴（200）时，本发明的方法还可以包括处理甘油以降低甘油粘度。

14. 发明申请

WO2008131172A1 CAN END WITH NEGATIVELY ANGLED WALL 审中-公开
标题翻译：可以结束与负面的墙壁
公开(公告)号：WO2008131172A1
公开(公告)日：2008-10-30
申请号：PCT/US2008/060744
申请日：2008-04-18
申请人： REXAM BEVERAGE CAN COMPANY , TURNER, Timothy , FORREST, Randall
发明人： TURNER, Timothy , FORREST, Randall
IPC分类号： B65D17/32
CPC分类号： B65D17/4012 , B65D2517/0014 , B65D2517/0062 , B65D2517/0082
摘要： An end (10) for a beverage can is described. The end has a product side (34), an opposing public side (32), a center panel (18), an annular countersink (16), a circumferential wall (14), and a curl (12). The center panel has a means for opening the end. The annular countersink extends circumferentially about the center panel. The circumferential wall extends upwardly from the countersink and has an angled portion (76) extending radially inwardly toward the center panel. The curl is located radially outward relative to the center panel and defines an outer perimeter of the end.
摘要翻译：描述了饮料罐的端部（10）。该端部具有产品侧（34），相对的公共侧（32），中心面板（18），环形埋头孔（16），周向壁（14）和卷曲（12）。中心面板有一个打开结局的手段。环形埋头孔沿中心面板周向延伸。圆周壁从埋头孔向上延伸，并且具有朝向中心面板径向向内延伸的倾斜部分（76）。卷曲相对于中心面板径向向外定位并且限定了端部的外周边。

15. 发明申请

WO2008091770A1 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS 审中-公开
标题翻译： 2-氨基吡啶衍生物作为GLUCOKINASE激活剂
公开(公告)号：WO2008091770A1
公开(公告)日：2008-07-31
申请号：PCT/US2008/051194
申请日：2008-01-16
申请人： ARRAY BIOPHARMA INC. , AICHER, Thomas Daniel , BOYD, Steven Armen , CHICARELLI, Mark Joseph , CONDROSKI, Kevin Ronald , GARREY, Rustam Ferdinand , HINKLIN, Ronald Jay , SINGH, Ajay , TURNER, Timothy M.
发明人： AICHER, Thomas Daniel , BOYD, Steven Armen , CHICARELLI, Mark Joseph , CONDROSKI, Kevin Ronald , GARREY, Rustam Ferdinand , HINKLIN, Ronald Jay , SINGH, Ajay , TURNER, Timothy M.
IPC分类号： C07D417/14 , C07D495/04 , A61K31/4439
CPC分类号： C07D495/04 , C07D417/14
摘要： Provided are compounds having the Formula (I) or salts thereof, wherein: L is O, S, SO, SO 2 , CHOH, C(O), or CH 2 ; D 2 is CR 12 or N; R 2 is aryl, heteroaryl, saturated or partially unsaturated cycloalkyl, or saturated or partially unsaturated heterocyclyl (optionally substituted with oxo), wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl are monocyclic or bicyclic and are further optionally substituted with one or more groups independently selected from C 1 -C 6 alkyl, F, Cl, Br, I, CF 3 , CN, OR 6 , C(=O)R 6 , C(=O)OR 6 , O(CH 2 ) n C(=O)OR 6 , C(=O)NR 6 R 7 , NO 2 and (1-6C alkyl)OR 6 ; R 3 is H, Br, OR 6 , SR 6 , C(O)OR 6 , C(O)NR 6 R 7 , C(O)R 6 , heteroaryl, or C 1 -C 6 alkyl substituted with one or more groups independently selected from V n -aryl, V n -OR 6 , V n - C(=O)OR 6 and V n -NR 6 R 7 ; R 11 is H or Cl; and R 13 is N-(1 -6C alkanoyl)piperidin-4-yl; that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
摘要翻译：提供具有式（I）或其盐的化合物，其中：L是O，S，SO，SO 2，CHOH，C（O）或CH 2 ; D 是CR 12或N; R 2是芳基，杂芳基，饱和或部分不饱和的环烷基或饱和或部分不饱和的杂环基（任选被氧代取代），其中所述芳基，杂芳基，环烷基和杂环基是单环或双环的，被一个或多个独立地选自C 1 -C 6烷基，F，Cl，Br，I，CF 3 N，CN， C（= O）R 6，C（= O）OR 6，O（CH 2）2， C（= O）OR 6，C（= O）NR 6 R 7，NO 2和（1-6C烷基）OR 6; R 3是H，Br，OR 6，SR 6，C（O）OR 6，C（O） O）NR 6 R 7，C（O）R 6，杂芳基或C 1 -C 6烷基，被一个或多个独立地选自以下的基团取代的亚烷基烷基：V n - 芳基，V n -OR 6，V C（= O）OR 6和V 6和-NR 6 R 7， SUP>; R 11是H或Cl; 和R 13是N-（1-6C烷酰基）哌啶-4-基; 其可用于治疗和/或预防由缺乏水平的葡糖激酶活性（例如糖尿病）介导的疾病。还提供了治疗或预防以葡萄糖激酶不足活性为特征的疾病和病症的方法，或者可以通过激活葡糖激酶治疗。

16. 发明申请

WO2005113351A1 CAN END 审中-公开
公开(公告)号：WO2005113351A1
公开(公告)日：2005-12-01
申请号：PCT/US2005/016546
申请日：2005-05-12
申请人： REXAM BEVERAGE CAN COMPANY , TURNER, Timothy , FORREST, Randall, G. , GOPALASWAMY, Rajesh
发明人： TURNER, Timothy , FORREST, Randall, G. , GOPALASWAMY, Rajesh
IPC分类号： B65D8/18
CPC分类号： B65D17/08 , B65D17/06 , B65D17/4012 , B65D17/502 , B65D2517/0007 , B65D2517/0011 , B65D2517/0061 , B65D2517/0076 , B65D2517/0079 , B65D2517/0082 , Y10S220/906
摘要： A can end member (10) has a center panel (18), a circumferential chuck wall, and a transition wall. The center panel is centered about a longitudinal axis (50) and has a peripheral edge. The center panel also has a step portion located radially outwardly from the longitudinal axis. The step portion has an annular convex portion joined to an annular concave portion and displaces at least a portion of the center panel vertically in a direction parallel to the longitudinal axis. The curl defines an outer perimeter of the end member. The circumferential chuck wall extends downwardly from the curl to the transition wall. The transition wall connects the chuck wall with the peripheral edge of the center panel. The transition wall comprises a folded portion. The folded portion has a first leg (56), a second leg (62), and a third leg (68). The first leg is directly connected to the chuck wall and joined to the second leg by a concave annular portion. The second leg is joined to the third leg by a convex annular portion, and the third leg is joined to the center panel. The convex annular portion has a radius of curvature greater than 0.002 ins.
摘要翻译：罐端构件（10）具有中心面板（18），周向卡盘壁和过渡壁。中心面板围绕纵向轴线（50）居中并且具有周边边缘。中心面板还具有从纵向轴线径向向外定位的台阶部分。台阶部分具有连接到环形凹部的环形凸部，并且在平行于纵向轴线的方向上垂直移动中心面板的至少一部分。卷曲限定了端部构件的外周。圆周卡盘壁从卷曲向下延伸到过渡壁。过渡壁将卡盘壁与中心面板的周边边缘连接。过渡壁包括折叠部分。折叠部分具有第一腿部（56），第二腿部（62）和第三腿部（68）。第一腿直接连接到卡盘壁上并通过凹入的环形部分连接到第二腿。第二腿部通过凸状的环状部分与第三腿部接合，第三腿部与中心面板接合。凸形环形部分具有大于0.002英寸的曲率半径。

17. 发明申请

WO2005044793A2 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS 审中-公开
标题翻译：含氮混合的杂环化合物
公开(公告)号：WO2005044793A2
公开(公告)日：2005-05-19
申请号：PCT/US2004/035648
申请日：2004-10-27
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , GYORKOS, Albert, Charles , CORRETTE, Christopher, Peter , CHO, Suk, Young , TURNER, Timothy, Mark , PRATT, Scott, Alan , ASO, Kazuyoshi , KORI, Masakuni , GYOTEN, Michiyo
发明人： GYORKOS, Albert, Charles , CORRETTE, Christopher, Peter , CHO, Suk, Young , TURNER, Timothy, Mark , PRATT, Scott, Alan , ASO, Kazuyoshi , KORI, Masakuni , GYOTEN, Michiyo
IPC分类号： C07D
CPC分类号： C07D235/30 , C07D471/04
摘要： There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and X 1 is an oxygen, a sulfur or - NR 5 -, or formula (A"): wherein X is a nitrogen and R 6 is an optionally substituted hydrocarbyl, R 1 is an amino substituted by two optionally substituted hydrocarbyl groups, R 2 is an phenyl, Y 1 is CR 3a or a nitrogen, Y 2 is CR 3b or a nitrogen and Y 3 is CR 3C or a nitrogen, provided that one or less of Y 1 , Y 2 , and Y 3 is nitrogen, W is a bond, -(CH 2 )n-, and Z is a bond, -NR 4 -, etc.; or a salt thereof or a prodrug thereof.
摘要翻译：提供了包含式（I）化合物的CRF受体拮抗剂：其中环A是由式（A'）表示的5元环：其中X是碳，X 1是氧，硫或-NR 5 - ，>或式（A“）：其中X是氮，R 6是任选取代的烃基，R 1是被两个任选取代的烃基取代的氨基， R 2是苯基，Y 1是CR 3a或氮，Y 2是CR 3b或氮和Y 3是CR 3或氮，条件是一个或更少的Y 1，Y 2和Y 3是氮，W是键， - （CH 2）n - ，Z是键，-NR 4 - ， - 等。 ;或其盐或其前药。

18. 发明申请

WO2013066869A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS 审中-公开
标题翻译：作为GPR119调节剂的哌啶取代的LACTAMS
公开(公告)号：WO2013066869A1
公开(公告)日：2013-05-10
申请号：PCT/US2012/062576
申请日：2012-10-30
申请人： ARRAY BIOPHARMA INC. , AICHER, Thomas Daniel , BENSCIK, Josef Roland , BOYD, Steven Armen , CONDROSKI, Kevin Ronald , FELL, Jay Bradford , FISCHER, John Peter , HINKLIN, Ronald Jay , PRATT, Scott , SINGH, Ajay , TURNER, Timothy M.
发明人： AICHER, Thomas Daniel , BENSCIK, Josef Roland , BOYD, Steven Armen , CONDROSKI, Kevin Ronald , FELL, Jay Bradford , FISCHER, John Peter , HINKLIN, Ronald Jay , PRATT, Scott , SINGH, Ajay , TURNER, Timothy M.
IPC分类号： C07D413/14 , C07D417/14 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/12 , A61P9/00 , A61P25/28 , A61P25/18
CPC分类号： C07D417/14 , C07D413/14
摘要： Compounds of Formula (I) and pharmaceutically acceptable salts thereof in which X 1 , X 2 , X 3 , L, R 3 , R 4 , R 5 , R 7 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
摘要翻译：其中X1，X2，X3，L，R3，R4，R5，R7和n具有本说明书中给出的含义的式（I）化合物及其药学上可接受的盐是GPR119的调节剂，可用于治疗或预防的疾病，例如但不限于2型糖尿病，糖尿病并发症，糖尿病症状，代谢综合征，肥胖症，血脂异常和相关病症。

19. 发明申请

WO2012125413A3 COMPOSITIONS FOR AMELIORATING SYSTEMIC INFLAMMATION AND METHODS FOR MAKING AND USING THEM 审中-公开
标题翻译：用于制备和使用它们的组合物用于制备和使用它们
公开(公告)号：WO2012125413A3
公开(公告)日：2012-12-27
申请号：PCT/US2012028312
申请日：2012-03-08
申请人： VICUS THERAPEUTICS LLC , MAKI JOHN , BASCOMB NEWELL , TURNER TIMOTHY J
发明人： MAKI JOHN , BASCOMB NEWELL , TURNER TIMOTHY J
IPC分类号： A61K31/135 , A61K9/20 , A61K9/48 , A61K31/40 , A61K31/404 , A61K31/535 , A61P25/00 , A61P37/00
CPC分类号： A61K31/7072 , A61J1/035 , A61K31/122 , A61K31/135 , A61K31/138 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/192 , A61K31/196 , A61K31/337 , A61K31/365 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/4045 , A61K31/405 , A61K31/407 , A61K31/415 , A61K31/427 , A61K31/454 , A61K31/4745 , A61K31/496 , A61K31/513 , A61K31/52 , A61K31/522 , A61K31/535 , A61K31/536 , A61K31/5377 , A61K31/5415 , A61K31/551 , A61K31/616 , A61K31/662 , A61K31/7056 , A61K38/13 , A61K38/212 , A61K39/39533 , A61K45/06 , A61K2300/00
摘要： In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid- derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.
摘要翻译：在替代实施方案中，本发明提供组合物，例如药物组合物和制剂，制剂，试剂盒和其它制造产品，例如包装在泡罩包装，带盖的泡罩或吸塑卡片中的单独包装或分开的示例性药物组合，或者包裹在纸，塑料或玻璃纸包装纸（例如，收缩包装），其包含至少两种活性成分的组合方案，其设计为通过靶向（抑制）两种不同的但收敛的信号传导途径，即交感神经系统和脂质衍生物自动化系统; 以及制备和使用这些组合物的方法。在替代实施方案中，本发明的组合物（例如，药物的组合）用于改善，减少，治疗，阻断或预防继发于感染例如病毒感染和/或再激活的炎症反应。

20. 发明申请

WO2012125413A2 COMPOSITIONS FOR AMELIORATING SYSTEMIC INFLAMMATION AND METHODS FOR MAKING AND USING THEM 审中-公开
标题翻译： AMELIORATING系统性炎症的组合物及其制备和使用方法
公开(公告)号：WO2012125413A2
公开(公告)日：2012-09-20
申请号：PCT/US2012/028312
申请日：2012-03-08
申请人： VICUS THERAPEUTICS, LLC , MAKI, John , BASCOMB, Newell , TURNER, Timothy, J.
发明人： MAKI, John , BASCOMB, Newell , TURNER, Timothy, J.
IPC分类号： A61K31/135 , A61K31/535 , A61K31/404 , A61K31/40 , A61K9/20 , A61K9/48 , A61P25/00 , A61P37/00
CPC分类号： A61K31/7072 , A61J1/035 , A61K31/122 , A61K31/135 , A61K31/138 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/192 , A61K31/196 , A61K31/337 , A61K31/365 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/4045 , A61K31/405 , A61K31/407 , A61K31/415 , A61K31/427 , A61K31/454 , A61K31/4745 , A61K31/496 , A61K31/513 , A61K31/52 , A61K31/522 , A61K31/535 , A61K31/536 , A61K31/5377 , A61K31/5415 , A61K31/551 , A61K31/616 , A61K31/662 , A61K31/7056 , A61K38/13 , A61K38/212 , A61K39/39533 , A61K45/06 , A61K2300/00
摘要： In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid- derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.
摘要翻译：在可选实施方式中，本发明提供了组合物，例如药物组合物和制剂，制剂，试剂盒和其他制造产品，例如包装在一起或分开包装在泡罩包装，带盖泡罩或泡罩卡中的示例性药物组合，或包裹在纸，塑料或玻璃纸包装物（例如收缩包装物）中，其包含至少两种活性成分的组合方案，其被设计为通过靶向（抑制）两种不同但收敛的信号传导途径，即交感神经系统和脂质衍生的autacoid系统; 以及制备和使用这些组合物的方法。在可选的实施方案中，本发明的组合物（例如药物组合）用于改善，减少，治疗，阻断或预防继发于感染（例如病毒感染和/或再激活）的炎症反应。 p>

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式